A review of data obtained from within the DISCOVER registry is offering clinicians insight into the prevalence of GLP-1 receptor agonists and SGLT2 inhibitors.

Presented at American Diabetes Association's 81st Scientific Sessions, information from the registry describes a slow, but gradual uptake in SGLT2 inhibitors but also outlines gaps in prescribing that leave many patients who could benefit the most without these medications.

Endocrinology Network talked to Dr. Suzanne Arnold, cardiologist at Saint Luke's Mid America Heart Institute, about the DISCOVER registry and the take-home message of its findings.

Read the full Endocrinology Network article: DISCOVER Details Gradual Uptake, Need for Improvement in Prescribing of SGLT2 Inhibitors, GLP-1 RAs